a public good project by the
Synthesis
Company
of California

© 2026

Kathleen Rickard | doi.page

0 works0 citations0 h-index

Kathleen Rickard

Verona Pharma (United Kingdom)(GB)Bridge Pharma (United States)(US)

Publications by Year

Research Areas

Asthma and respiratory diseases, Respiratory and Cough-Related Research, Chronic Obstructive Pulmonary Disease (COPD) Research, Inhalation and Respiratory Drug Delivery, Allergic Rhinitis and Sensitization

Most-Cited Works

→ Efficacy of Salmeterol Xinafoate in the Treatment of COPD(1999)514 cited
→ Use of a Long-acting Inhaled β2-Adrenergic Agonist, Salmeterol Xinafoate, in Patients with Chronic Obstructive Pulmonary Disease(2001)261 cited
→ Salmeterol Plus Theophylline Combination Therapy in the Treatment of COPD(2001)259 cited
→ Fluticasone propionate/salmeterol combination provides more effective asthma control than low-dose inhaled corticosteroid plus montelukast(2000)226 cited
→ The addition of salmeterol to fluticasone propionate versus increasing the dose of fluticasone propionate in patients with persistent asthma(1999)152 cited
→ Comparison of inhaled salmeterol and oral zafirlukast in patients with asthma(1999)144 cited

→ Salmeterol Powder Provides Significantly Better Benefit Than Montelukast in Asthmatic Patients Receiving Concomitant Inhaled Corticosteroid Therapy(2001)

141 cited

No growth suppression in children treated with the maximum recommended dose of fluticasone propionate aqueous nasal spray for one year.(2003)

→ Addition of salmeterol to low-dose fluticasone versus higher-dose fluticasone: An analysis of asthma exacerbations(2001)129 cited

→ Ensifentrine, a Novel Phosphodiesterase 3 and 4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease: Randomized, Double-Blind, Placebo-controlled, Multicenter Phase III Trials (the ENHANCE Trials)(2023)127 cited